Evidence map›Paper›PMID 39663784›Full record

ReviewJournal of cellular and molecular medicine2024

The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double-edge sword.

Ayah Talal Zaidalkilani, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Athanasios Alexiou, Marios Papadakis, Ammar Al-Farga, Othman A Alghamdi, Mostafa M Bahaa, Mohammed Alrouji, Mohammed S Alshammari and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cellular and molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ayah Talal ZaidalkilaniDepartment of Nutrition, Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, 11196, Jordan.
Hayder M Al-KuraishyDepartment of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Ali I Al-GareebDepartment of Clinical pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Athanasios AlexiouDepartment of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.ORCID 0000-0002-2206-7236
Marios PapadakisDepartment of Surgery II, University Hospital Witten-Herdecke, Heusnerstrasse 40, University of Witten-Herdecke, Wuppertal, Germany.
Ammar Al-FargaDepartment of Biochemistry, College of Science University of Jeddah, Jeddah, Saudi Arabia.
Othman A AlghamdiDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
Mostafa M BahaaPharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.ORCID 0000-0003-3332-4573
Mohammed AlroujiDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
Mohammed S AlshammariDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, Saudi Arabia.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The metabolic syndrome (MetS) is a clustering of abdominal obesity, hypertension, hyperglycaemia, hypertriglyceridemia and low high-density lipoprotein (HDL) level. MetS development is affected by endocrine hormones such as prolactin (PRL) hormone which induce insulin resistance and central obesity because PRL is implicated in the pathogenesis of MetS. Pituitary PRL controls mammary gland, however extra-pituitary PRL is highly intricate in the regulation of adipose tissue function. In addition, cAMP activators enhance expression and release of PRL which involved in the control of lipogenesis and energy homeostasis. Consequently, hyperprolactinaemia may be associated with the development of MetS. However, normal physiological level of PRL is essential for insulin sensitivity and regulation of adipose tissue function and energy metabolism. Therefore, PRL has dual effects on the components of MetS. Hence, the present review aims to discuss the modulatory mechanistic role of PRL on MetS regarding its beneficial and detrimental effects.

Indexed as

Metabolic SyndromeProlactinAdipose TissueAnimalsEnergy MetabolismHumansInsulin ResistanceProlactininsulin resistancemetabolic syndromeprolactin

Identifiers

PMID39663784
PMCPMC11635126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.